NCT04689919View on ClinicalTrials.gov

Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 19, 2022

Primary Completion Date

March 7, 2022

Study Completion Date

April 5, 2022

Conditions
Bioequivalence
Interventions
DRUG

Rivaroxaban 20 MG Oral Tablet

The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.

Trial Locations (1)

75270

Center for Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, university of Karachi, Karachi

All Listed Sponsors
collaborator

The Searle Company Limited Pakistan

INDUSTRY

collaborator

Center for Bioequivalence Studies and Clinical Research (CBSCR), HEJ Research Institute of chemistry, University of Karachi

UNKNOWN

lead

University of Karachi

OTHER